MentionFox
Home › funding signals › Intercure Ltd.
Form D · on the record

Intercure Ltd. — Form D filing, August 2026

Intercure Ltd. filed a Form D with the Securities and Exchange Commission on 2026-08-19.

Intercure Ltd. filed a Form D notice of an exempt securities offering with the SEC on August 19, 2026. Its industry group is Pharmaceuticals. It names Alexander Rabinovich (Chief Executive Officer and Chairman of the Board of Directors), David Salton (Director), Lennie Michelson Grinbaum (Director) (SEC Form D, August 19, 2026).

5 more Pharmaceuticals raises within 90 days of this one ↓

Is this your company?

Key facts

Run the free check on Intercure Ltd. →

Sell to companies like Intercure Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Intercure Ltd.

New Form D on file · 2026-08-19 · the record

$0
raise on the record
D
filing
15
investors in
ISRAEL
based
Open the record →

What the record says

FilingForm D
Filed2026-08-19
Industry groupPharmaceuticals
Entity typeCorporation
Incorporated inISRAEL
BasedHERTZLIYA, ISRAEL
CIK1857030
Accession0001493152-26-039252

Pitching, partnering or investing alongside them? See who really runs and owns Intercure Ltd.

Free to see. No signup.

Keep reading

More on the people and the money behind Intercure Ltd., from the filings we hold.

More raises like this

Pharmaceuticals raises filed within 90 days of this one, largest first.

What do you want to do with Intercure Ltd.?

Get the full cited report on Intercure Ltd.

What the filing shows about Intercure Ltd.

  • 15 investors had already put money in when it filed.
  • The filing names 5 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Intercure Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Who the filing names, and in what role

The filing gives Intercure Ltd.'s address as 85 Medinat Ha-Yehudim St., Hertzliya, L3 4676670.

What the filing says

  • Offered: an open-ended amount (the filing says Indefinite). Sold: nothing yet. Left to sell: open-ended (Indefinite). (filing)
  • Investors: 15 had already invested. (filing)
  • Date of first sale: June 15, 2026. (filing)
  • Types of securities: Equity; Options, warrants or other rights to acquire another security. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)
  • On the amounts offered and sold: the filing adds “The transaction consisted of the first closing of an acquisition of ISHI (Botanico Ltd.) by Intercure Ltd. in consideration of InterCure's Ltd.'s ordinary shares and options to purchase ordinary shares.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Intercure Ltd. See pricing

Is Intercure Ltd. a real, registered company?

Intercure Ltd. is a registered filer with the SEC (CIK 1857030) and has filed since 2026-08-19. 1 filing is on record, the latest on 2026-08-19.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Intercure Ltd.?

Intercure Ltd.'s Form D of 2026-08-19 names Alexander Rabinovich, David Salton, Lennie Michelson Grinbaum and 2 more as its officers, directors or promoters.

Pharmaceuticals · by week

Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week.

Want the whole picture on Intercure Ltd.?

What the filing shows about Intercure Ltd.

  • 15 investors had already put money in when it filed.
  • The filing names 5 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Intercure Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Intercure Ltd. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Intercure Ltd.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (intercure.co).

RSS

Tools for this story

Each opens in a new tab, filled in for Intercure Ltd.. With no account yet, you sign up free and land on the result.

Cite this page

Permanent URL: https://mentionfox.com/funding/intercure-ltd-form-d-26000001
Last updated 2026-10-20
Primary record: SEC filing 1 · SEC filing 2
Intercure Ltd. — SEC Form D filing, August 2026. MentionFox, 2026-10-20. https://mentionfox.com/funding/intercure-ltd-form-d-26000001